inclusion criteria: 1. provide written informed consent 2. subjects age \> 18 years at the time of signing the informed consent form. 3. male or female 4. must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. 5. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg \< pao2/fio2 \</= 200 mm hg with peep \>/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 \</= 100 mm hg with peep \>/= 5 cm h2o 6. hospitalized and symptomatic (cough, fevers, sob, or sputum production) 7. adequate venous access 8. ability to provide informed consent or an authorized representative can sign the informed consent 9. for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. 10. must agree to comply with all study requirements and be willing to complete all study visits 11. willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.

inclusion criteria: 1. provide written informed consent 2. subjects age \> 18 years at the time of signing the informed consent form. 3. male or female 4. must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. 5. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg \< pao2/fio2 \</= 200 mm hg with peep \>/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 \</= 100 mm hg with peep \>/= 5 cm h2o 6. hospitalized and symptomatic (cough, fevers, sob, or sputum production) 7. adequate venous access 8. ability to provide informed consent or an authorized representative can sign the informed consent 9. for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. 10. must agree to comply with all study requirements and be willing to complete all study visits 11. willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.

inclusion criteria: provide written informed consent subjects age > 18 years at the time of signing the informed consent form. male or female must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg < pao2/fio2 </= 200 mm hg with peep >/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 </= 100 mm hg with peep >/= 5 cm h2o hospitalized and symptomatic (cough, fevers, sob, or sputum production) adequate venous access ability to provide informed consent or an authorized representative can sign the informed consent for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.

inclusion criteria: provide written informed consent subjects age > 18 years at the time of signing the informed consent form. male or female must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg < pao2/fio2 </= 200 mm hg with peep >/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 </= 100 mm hg with peep >/= 5 cm h2o hospitalized and symptomatic (cough, fevers, sob, or sputum production) adequate venous access ability to provide informed consent or an authorized representative can sign the informed consent for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. must agree to comply with all study requirements and be willing to complete all study visits willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.

inclusion criteria: 1. provide written informed consent 2. subjects age > 18 years at the time of signing the informed consent form. 3. male or female 4. must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. 5. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg < pao2/fio2 </= 200 mm hg with peep >/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 </= 100 mm hg with peep >/= 5 cm h2o 6. hospitalized and symptomatic (cough, fevers, sob, or sputum production) 7. adequate venous access 8. ability to provide informed consent or an authorized representative can sign the informed consent 9. for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. 10. must agree to comply with all study requirements and be willing to complete all study visits 11. willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.

inclusion criteria: 1. provide written informed consent 2. subjects age > 18 years at the time of signing the informed consent form. 3. male or female 4. must have a clinical diagnosis of covid-19, with at least one of clinical symptoms (e.g., fever ≥38°c, fatigue, cough) and a positive result by the reverse- transcription polymerase chain reaction (rt-pcr) testing or equivalent. 5. individuals with moderately to severe covid-19 symptoms. moderate ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: 100 mm hg < pao2/fio2 </= 200 mm hg with peep >/=5 cm h2o severe ards according to berlin criteria: symptoms include: abnormal chest imaging or any degree of hypoxia requiring supplemental oxygen. bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. oxygenation: pao2/fio2 </= 100 mm hg with peep >/= 5 cm h2o 6. hospitalized and symptomatic (cough, fevers, sob, or sputum production) 7. adequate venous access 8. ability to provide informed consent or an authorized representative can sign the informed consent 9. for female patients only, willingness to use fda- recommended birth control (http://www.fda.gov/downloads/forconsumers/byau dience/forwomen/freepublications/ucm356451.pdf ) until 6 months post treatment. 10. must agree to comply with all study requirements and be willing to complete all study visits 11. willingness of study participant to accept this treatment arm, and signed informed consent; need in- patient admission.